Literature DB >> 12162761

Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Michael S Roberts1, Beatrice M Magnusson, Frank J Burczynski, Michael Weiss.   

Abstract

Enterohepatic recycling occurs by biliary excretion and intestinal reabsorption of a solute, sometimes with hepatic conjugation and intestinal deconjugation. Cycling is often associated with multiple peaks and a longer apparent half-life in a plasma concentration-time profile. Factors affecting biliary excretion include drug characteristics (chemical structure, polarity and molecular size), transport across sinusoidal plasma membrane and canniculae membranes, biotransformation and possible reabsorption from intrahepatic bile ductules. Intestinal reabsorption to complete the enterohepatic cycle may depend on hydrolysis of a drug conjugate by gut bacteria. Bioavailability is also affected by the extent of intestinal absorption, gut-wall P-glycoprotein efflux and gut-wall metabolism. Recently, there has been a considerable increase in our understanding of the role of transporters, of gene expression of intestinal and hepatic enzymes, and of hepatic zonation. Drugs, disease and genetics may result in induced or inhibited activity of transporters and metabolising enzymes. Reduced expression of one transporter, for example hepatic canalicular multidrug resistance-associated protein (MRP) 2, is often associated with enhanced expression of others, for example the usually quiescent basolateral efflux MRP3, to limit hepatic toxicity. In addition, physiologically relevant pharmacokinetic models, which describe enterohepatic recirculation in terms of its determinants (such as sporadic gall bladder emptying), have been developed. In general, enterohepatic recirculation may prolong the pharmacological effect of certain drugs and drug metabolites. Of particular importance is the potential amplifying effect of enterohepatic variability in defining differences in the bioavailability, apparent volume of distribution and clearance of a given compound. Genetic abnormalities, disease states, orally administered adsorbents and certain coadministered drugs all affect enterohepatic recycling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12162761     DOI: 10.2165/00003088-200241100-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  289 in total

Review 1.  Metabolism of drugs and other xenobiotics in the gut lumen and wall.

Authors:  K F Ilett; L B Tee; P T Reeves; R F Minchin
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

2.  Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data.

Authors:  T Izumi; K Hosiyama; S Enomoto; K Sasahara; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  1997-03       Impact factor: 4.030

3.  Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.

Authors:  James E Patrick; Teddy Kosoglou; Kathe L Stauber; Kevin B Alton; Stephen E Maxwell; Yali Zhu; Paul Statkevich; Robert Iannucci; Swapan Chowdhury; Melton Affrime; Mitchell N Cayen
Journal:  Drug Metab Dispos       Date:  2002-04       Impact factor: 3.922

4.  Noncompartmental area under the curve determinations for drugs that cycle in the bile.

Authors:  W A Colburn; R W Lucek
Journal:  Biopharm Drug Dispos       Date:  1988 Sep-Oct       Impact factor: 1.627

5.  Estimation of area under the curve for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

6.  Hypercholeresis induced by ursodeoxycholic acid and 7-ketolithocholic acid in the rat: possible role of bicarbonate transport.

Authors:  M Dumont; S Erlinger; S Uchman
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

7.  Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.

Authors:  R B Kim; B Leake; M Cvetkovic; M M Roden; J Nadeau; A Walubo; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

8.  Biliary excretion of some diquaternary ammonium cations in the rat, guinea pig and rabbit.

Authors:  R D Hughes; P Millburn; R T Williams
Journal:  Biochem J       Date:  1973-12       Impact factor: 3.857

9.  In liver transplantation, T tube bile represents total bile flow: physiological and scintigraphic studies on biliary secretion of organic anions.

Authors:  R Lenzen; A Bähr; H Eichstädt; U Marschall; W O Bechstein; P Neuhaus
Journal:  Liver Transpl Surg       Date:  1999-01

10.  A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil.

Authors:  R Zhang; T Liu; S J Soong; R B Diasio
Journal:  Biochem Pharmacol       Date:  1993-05-25       Impact factor: 5.858

View more
  135 in total

1.  A compartmental model of hepatic disposition kinetics: 1. Model development and application to linear kinetics.

Authors:  Yuri G Anissimov; Michael S Roberts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-04       Impact factor: 2.745

2.  Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.

Authors:  Jackie C Bloomer; Mike Nash; Alison Webb; Bruce E Miller; Aili L Lazaar; Claire Beaumont; William J Guiney
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 3.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

4.  Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.

Authors:  Els Van Peer; Noel Downes; Christophe Casteleyn; Chris Van Ginneken; Arie Weeren; Steven Van Cruchten
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-19       Impact factor: 2.745

Review 5.  Bile acid transporter-mediated oral drug delivery.

Authors:  Feiyang Deng; You Han Bae
Journal:  J Control Release       Date:  2020-07-22       Impact factor: 9.776

6.  Physiologically based synthetic models of hepatic disposition.

Authors:  C Anthony Hunt; Glen E P Ropella; Li Yan; Daniel Y Hung; Michael S Roberts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

7.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

8.  Enterohepatic recirculation of bioactive ginger phytochemicals is associated with enhanced tumor growth-inhibitory activity of ginger extract.

Authors:  Sushma R Gundala; Rao Mukkavilli; Chunhua Yang; Pooja Yadav; Vibha Tandon; Subrahmanyam Vangala; Satya Prakash; Ritu Aneja
Journal:  Carcinogenesis       Date:  2014-01-15       Impact factor: 4.944

9.  Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.

Authors:  Peter L Bonate; Simon Floret; Craig Bentzen
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 10.  Developing a metagenomic view of xenobiotic metabolism.

Authors:  Henry J Haiser; Peter J Turnbaugh
Journal:  Pharmacol Res       Date:  2012-08-09       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.